| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 06/30/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 06/30/2022 | 41.51% | Stifel | $5 → $1.5 | Downgrades | Buy → Hold |
| 05/23/2022 | 2541.51% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 04/18/2022 | 2918.87% | HC Wainwright & Co. | $50 → $32 | Maintains | Buy |
| 12/10/2021 | 654.72% | Oppenheimer | $15 → $8 | Maintains | Outperform |
| 11/09/2021 | 4616.98% | HC Wainwright & Co. | $100 → $50 | Maintains | Buy |
| 10/27/2021 | 1315.09% | Stifel | $40 → $15 | Maintains | Buy |
| 03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 03/02/2021 | 3484.91% | Oppenheimer | → $38 | Initiates Coverage On | → Outperform |
| 03/02/2021 | 3673.58% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/01/2021 | 9333.96% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
Angion Biomedica Questions & Answers
The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by HC Wainwright & Co. on July 18, 2022. The analyst firm set a price target for $0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Angion Biomedica (NASDAQ: ANGN) was provided by HC Wainwright & Co., and Angion Biomedica downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Angion Biomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Angion Biomedica was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
While ratings are subjective and will change, the latest Angion Biomedica (ANGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Angion Biomedica (ANGN) is trading at is $1.06, which is out of the analyst's predicted range.